EDAP TMS Earnings Call Highlights HIFU Growth Momentum

EDAP TMS S.A. ((EDAP)) has held its Q4 earnings call. Read on for the main highlights of the call.

EDAP TMS S.A. struck an upbeat tone on its earnings call, underscoring powerful momentum in its core Focal One HIFU franchise even as legacy lines dragged on reported results. Management emphasized record system placements, accelerating procedure volumes, and expanding academic adoption, arguing that these high‑margin growth drivers more than offset short‑term margin pressure and widening losses.

Strong Core HIFU Revenue Growth

Full‑year HIFU revenue jumped to €33.1 million in 2025, a 39% increase from €23.8 million in 2024, confirming the segment as EDAP’s clear growth engine. In the fourth quarter alone, HIFU revenue reached €11.7 million, up 34% year over year, demonstrating sustained demand despite broader capital equipment volatility.

Record System Placements and Cash Sales

The company delivered a record quarter with 15 Focal One placements in Q4, including 14 cash sales, highlighting robust customer willingness to commit capital. For 2025, EDAP sold 35 Focal One systems, with the U.S. contributing 10 cash sales in the quarter, signaling growing commercial traction in its key market.

Procedure Volume Acceleration

U.S. Focal One procedure volumes increased 28% in Q4 2025 versus the prior‑year period, creating a expanding recurring revenue base. Treatment‑driven revenue rose 19% for the full year and 22% in Q4, underscoring that installed systems are being actively utilized rather than sitting idle.

Installed Base Expansion and Academic Penetration

EDAP’s installed base climbed to 165 Focal One units, with deeper roots in leading academic centers that shape clinical practice. The system is now in 55% of NCCN member institutions and 63% of SUO teaching hospitals, while 10 U.S. health systems run two or more programs, including five within the Cleveland Clinic network.

Regulatory and Technology Milestones

The company secured FDA clearance in November 2025 for its latest Focal One evolution, adding advanced ultrasound imaging and AI‑enabling capabilities that should improve competitiveness. EDAP also launched the Focal One i commercially in 2025 following earlier price adjustments, aiming to enhance both clinical value and pricing power.

Favorable Reimbursement Developments

Reimbursement trends turned more supportive, with the 2026 outpatient facility payment averaging $9,671, a 4.6% increase over 2025. On the physician side, total facility RVUs were set at 26.33, and Focal One offers 28%–67% higher RVUs than alternative ablative options, enhancing the economic incentive to adopt the technology.

International Market Expansion

Beyond the U.S., EDAP expanded into new geographies, booking four cash sales outside the U.S. in Q4, including first‑ever placements in India and Argentina. Additional systems in Italy and Spain further extend the company’s footprint in underpenetrated markets and diversify growth away from a single country.

Improved Liquidity and Inventory Management

On the balance sheet, inventory declined to €10.9 million from €13.8 million sequentially, indicating tighter operational discipline as legacy businesses wind down. Cash and equivalents increased to €17.4 million from €10.6 million, helped by the European Investment Bank Tranche A drawdown, giving EDAP more flexibility to fund growth.

Clinical Indication Expansion and Education

Management highlighted efforts to broaden the clinical reach of its technology, including ongoing BPH Phase I/II work in Europe and a new BPH trial in South America in collaboration with Mount Sinai. Programs in endometriosis and stepped‑up surgeon education, including major conferences and a first international symposium on robotic focal therapy, aim to build long‑term procedural demand.

Total Revenue Decline and Noncore Weakness

Despite the HIFU surge, total 2025 revenue slipped 3% to €62.4 million as noncore distribution and ESWL businesses fell 27% for the year and 38% in Q4. ESWL now represents roughly one‑fifth to one‑quarter of noncore revenue, and management signaled an ongoing wind‑down, meaning reported revenue may remain pressured while mix improves.

Gross Margin Pressure from Tariffs and Reserves

Profitability was squeezed, with Q4 gross margin on net sales declining to 42.6% from 44.8% a year earlier, mainly because of U.S. Section 232 tariffs on finished goods imported from France and inventory reserves on legacy parts. Management suggested a normalized Q4 margin near 46.9% and has budgeted about $2.5 million in tariffs for 2026, signaling continued headwinds but with visibility.

Widening Operating and Net Losses

Losses widened as EDAP invests behind growth and absorbs noncash and financial charges: Q4 operating loss was €5.2 million versus €3.7 million in the prior year. Net loss expanded to €8.2 million, or €0.22 per share, driven by a roughly €2.5 million noncash warrant charge, interest tied to the EIB drawdown, and about €2 million of negative currency impact.

Seasonality, Capital Lumpiness and Financial Volatility

Management reminded investors that the business remains seasonal, with Q4 typically the strongest quarter and Q3 the weakest, and that capital sales can be lumpy from period to period. Currency swings and below‑the‑line items like warrant valuation adjustments added further volatility to reported net income, masking underlying HIFU operating momentum.

Forward‑Looking Guidance and Outlook

EDAP reiterated 2026 guidance for core HIFU revenue of $50–$54 million, implying robust growth of 34%–45% over 2025, alongside $22–$26 million in combined noncore revenue. The company expects slightly under half of revenue in the first half of the year, with Q4 again the strongest and Q3 the weakest, while planning for roughly $2.5 million of Section 232 tariffs as it leans on capital placements and rising procedures to drive expansion.

EDAP’s earnings call painted a picture of a company in transition, where a rapidly scaling HIFU platform is overshadowing shrinking legacy segments and near‑term margin noise. For investors, the key takeaway is that record system sales, rising procedure volumes, and strengthening reimbursement support a constructive long‑term growth story, even as reported earnings remain choppy in the medium term.